Unknown PHASE2 INTERVENTIONAL 1-arm NCT00813137

FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer

A Multi-center Study of Folfox4 Combined With Recombinant Human Endostatin(Endostar)in Advanced Colorectal Cancer

Sponsor: Simcere Pharmaceutical Co., Ltd

Interventions Folfox4 plus recombinant human endostatin (Endostar)

Updated 5 times since 2017 Last updated: Dec 6, 2009 Started: Oct 31, 2008 Primary completion: Oct 31, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00813137, this PHASE2 trial focuses on Colorectal Neoplasms and remains ongoing. Sponsored by Simcere Pharmaceutical Co., Ltd, it has been updated 5 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Simcere Pharmaceutical Co., Ltd
The Affiliated Changzhou Tumor Hospital of Suzhou University

Data source: Simcere Pharmaceutical Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Changzhou, China
• Nanjing, China